Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1161522 | 1.00 | HPGDS (0.48) | HPGDSALDH1A1KDM4EHRH3EPHX2 | |
| SCHEMBL15551565 | 0.89 | EPHX2 (0.48) | HPGDSALDH1A1KDM4EHRH3EPHX2 | |
| SCHEMBL15551563 | 0.89 | EPHX2 (0.48) | HPGDSALDH1A1KDM4EHRH3EPHX2 | |
| SCHEMBL11029299 | 0.87 | HRH3 (0.46) | HPGDSHRH3MAPTKCNH2 | |
| SCHEMBL17739185 | 0.87 | KDM4E (0.51) | HPGDSALDH1A1KDM4EHRH3EPHX2 | |
| SCHEMBL18532945 | 0.87 | HRH3 (0.46) | HPGDSHRH3MAPTKCNH2 | |
| SCHEMBL18532923 | 0.87 | KDM4E (0.51) | HPGDSALDH1A1KDM4EHRH3EPHX2 | |
| SCHEMBL11942496 | 0.87 | HRH3 (0.46) | HPGDSHRH3MAPTKCNH2 | |
| SCHEMBL19646480 | 0.86 | HPGDS (0.50) | HPGDSHRH3EPHX2FAAH | |
| SCHEMBL15550938 | 0.85 | HRH3 (0.53) | ALDH1A1KDM4EHRH3EPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10406144-B2 | SIP modulating agents | BIOGEN MA INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2019-07-11 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN MA INC. | 2018-05-17 | — | — | US | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827258-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN MA INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2014-10-16 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802659-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | BIOGEN IDEC MA INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2461683-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | Biogen Idec MA Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| WO-2011017561-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | BIOGEN IDEC MA INC. (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309190-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | HPGDS 1572/4885ALDH1A1 4545/4885KDM4E 3357/4885 |
| US-10406144-B2 | SIP modulating agents | S1PR2, S1PR1, S1PR3 | HPGDS 95/4885ALDH1A1 2802/4885KDM4E 3487/4885 |
| US-20180133233-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | HPGDS 1572/4885ALDH1A1 4545/4885KDM4E 3357/4885 |
| US-20120190649-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | HPGDS 1263/4885ALDH1A1 3931/4885KDM4E 3227/4885 |
| US-10166250-B2 | Bicyclic aryl sphingosine 1-phosphate analogs | S1PR1, S1PR3, S1PR4 | HPGDS 1572/4885ALDH1A1 4545/4885KDM4E 3357/4885 |
| US-20190209592-A1 | BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS | S1PR1, S1PR3, S1PR4 | HPGDS 1263/4885ALDH1A1 3931/4885KDM4E 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.